Royal London Asset Management Ltd. Acquires 991 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Royal London Asset Management Ltd. grew its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 6.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 16,425 shares of the medical research company’s stock after purchasing an additional 991 shares during the period. Royal London Asset Management Ltd.’s holdings in Charles River Laboratories International were worth $3,032,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Virtu Financial LLC bought a new position in Charles River Laboratories International during the 3rd quarter worth $601,000. JPMorgan Chase & Co. raised its position in shares of Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after acquiring an additional 85,759 shares during the last quarter. State Street Corp lifted its stake in shares of Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after acquiring an additional 41,421 shares during the period. Janus Henderson Group PLC boosted its holdings in Charles River Laboratories International by 7.6% in the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after acquiring an additional 3,268 shares during the last quarter. Finally, Neo Ivy Capital Management acquired a new stake in Charles River Laboratories International during the 3rd quarter valued at approximately $966,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In other news, COO Birgit Girshick purchased 1,514 shares of the stock in a transaction dated Thursday, February 20th. The shares were purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This represents a 2.83 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $167.29 on Tuesday. The firm has a market capitalization of $8.55 billion, a P/E ratio of 1,115.28, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The business’s fifty day simple moving average is $165.66 and its 200 day simple moving average is $183.49. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $273.57.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.46 earnings per share. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of recent analyst reports. Morgan Stanley dropped their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target on the stock in a research report on Monday, March 3rd. Bank of America decreased their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, Citigroup upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Hold” and a consensus target price of $189.77.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).